<DOC>
	<DOCNO>NCT00451074</DOCNO>
	<brief_summary>The purpose study determine safety give intravenous ( IV ) gentamicin boys Duchenne muscular dystrophy stop codon mutation .</brief_summary>
	<brief_title>Six Month Study Gentamicin Duchenne Muscular Dystrophy With Stop Codons</brief_title>
	<detailed_description>The primary purpose second cohort see IV Medication , gentamicin , safe give twice week six month boys Duchenne muscular dystrophy ( DMD ) . Secondarily , want know gentamicin help strengthen muscle boys DMD particular type genetic mutation know stop codon . The gentamicin think allow `` read-through '' type mutation would allow production dystrophin , protein lack boy DMD .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Age 520 year Duchenne muscular dystrophy document write report stop codon mutation analysis dystrophin gene . Subject capable cooperate efficacy safety test Absent dystrophin muscle biopsy Subjects may untreated , take prednisone comparable corticosteroid Subjects take corticosteroid must dose least 3 month ( 90 day ) prior start study . Known allergy aminoglycoside sulfate compound Current use potential nephrotoxic ototoxic drug Current use corticosteroid stable 3 month ( 90 ) day Known mutation nucleotide 1555 12S rRNA gene mitochondrial DNA ( predisposes aminoglycoside hear loss commercially available via Athena Diagnostics Lab ) . This DNA test ( Hearing susceptibility test ) make available funding grant . Inability hear within range 0 25 dB hearing frequency pure tone audiometry Cystatin C equal &gt; 1.4mg/L Other medical condition would impede conduct study ( e.g. , congestive heart failure )</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Stop codon mutation</keyword>
</DOC>